Letermovir Uses, Dosage, Side Effects and Interactions
Prevymis
Prevymis was the first letermovir product the FDA approved, in November 2017. No generic is listed as injections, oral pellets and tablets.
Letermovir (Prevymis) is an antiviral medicine used to prevent cytomegalovirus (CMV) infection and disease in certain transplant patients.
Quick links
Ask Anything About LetermovirType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Letermovir in Short
- Drug class Cytomegalovirus DNA Terminase Complex Inhibitor How the FDA classifies it
What it treatsPrevymis is used to prevent CMV (cytomegalovirus) infection and disease in adults and children 6 months of age and older who have had an allogeneic hematopoietic stem cell transplant (a stem cell transplant from a donor) and who already carry the CMV virus themselves.
- How you get it Prescription only
- Comes asInjection, oral pellets and tabletAvailable strengths
Injection (into a vein)
- 20 mg/mL
Oral pellets (by mouth)
- 20 mg
- 120 mg
Tablet (by mouth)
- 240 mg
- 480 mg
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Letermovir (tablet); Prevymis (tablet)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- What Medicaid pays
- Prevymis (brand)$270.21 to $270.60 a tablet
- Injections and oral pellets: no national price found
- Generic launchFebruary 2033 Our estimate for the first generic of Prevymis
The Pharmacist’s Take
Letermovir (Prevymis) is an antiviral that prevents cytomegalovirus (CMV) after a donor stem cell or high-risk kidney transplant by blocking the step where the virus packages its DNA into new copies; on the U.S. market since about 2017 and with no generic listed yet, it has become a standard preventive choice after stem cell transplant. Most people tolerate it well, and it is gentler on blood counts than older CMV antivirals; nausea, diarrhea, vomiting and some leg or ankle swelling are the usual complaints. The real issue is interactions, and a few combinations are never allowed (pimozide, ergot migraine drugs, or simvastatin or pitavastatin taken with cyclosporine).
Key Takeaways From the HelloPharmacist Team
- Swallow the tablet whole once daily, with or without food, through day 100 after stem cell or day 200 after kidney transplant.
- Expect closer tacrolimus or sirolimus blood level checks while on letermovir, since it pushes their levels up.
- Call your care team promptly about unexplained muscle pain or weakness, which can signal muscle breakdown (rhabdomyolysis) from a statin interaction.
- Avoid St. John's Wort and flag any new seizure medicine or rifampin-type antibiotic, since these can weaken letermovir's protection.
Patient Information Guide for Letermovir
What It’s Used For
Prevymis (letermovir) is an antiviral medicine approved to prevent CMV (cytomegalovirus) in specific groups of transplant patients.
- Stem cell transplant (HSCT) recipients: Prevymis is approved to prevent CMV infection and disease in adults and children 6 months of age and older, weighing at least 6 kg, who received a stem cell transplant from a donor and who themselves carry the CMV virus (CMV-seropositive).
- Kidney transplant recipients: Prevymis is approved to prevent CMV disease in adults and children 12 years of age and older, weighing at least 40 kg, who received a kidney transplant and are at high risk — meaning the donor tested CMV-positive and the recipient tested CMV-negative (D+/R-).
How It Works
Letermovir works by blocking a viral protein complex called the CMV DNA terminase complex. This complex is essential for the cytomegalovirus to cut and package its DNA into new viral particles. Without this step, the virus cannot make functional copies of itself and spread through the body. Because this target is specific to CMV and not found in human cells, letermovir can attack the virus without using the same mechanism as older antivirals.
Drug Class
Drug Class
- Cytomegalovirus DNA Terminase Complex Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Cytomegalovirus DNA Terminase Complex Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Cytochrome P450 2C9 Inducers
- Cytochrome P450 2C19 Inducers
- Cytochrome P450 2C8 Inhibitors
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Cytochrome P450 3A Inhibitors
- DNA Terminase Complex Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Letermovir in the FDA’s index.
From our Patient Information GuideLetermovir works by blocking a viral protein complex called the CMV DNA terminase complex. This complex is essential for the cytomegalovirus to cut and package its DNA into new viral particles. Read How Letermovir Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Letermovir in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Other antivirals
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Prevymis is taken once daily, by mouth or by IV infusion, depending on which form your care team prescribes. Tablets can be taken with or without food and must be swallowed whole.
Oral pellets are mixed with soft food or administered through a feeding tube. The IV infusion is given over one hour in a clinical setting and is reserved for patients who cannot take oral medication.
- For stem cell transplant patients, treatment is typically started between the day of transplant and Day 28, and continued through Day 100 — or up to Day 200 for those at higher risk of late CMV reactivation.
- For kidney transplant patients, treatment starts between Day 0 and Day 7 after transplant and continues through Day 200.
- If you also take cyclosporine, your dose of Prevymis will be adjusted — do not change your dose on your own.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Letermovir Taken by Mouth
Preventing CMV infection after a stem cell transplant
Adults and children 12 years and older weighing at least 30 kg Usual dose 480 mg once a day
- 480 mg once daily orally (one 480 mg tablet or two 240 mg tablets
- Four 120 mg packets of oral pellets for patients who cannot swallow tablets) through 100 days post-HSCT
Good to know
May be continued through Day 200 post-HSCT in patients at risk for late CMV infection and disease; initiate between Day 0 and Day 28 post-HSCT
HSCT stands for hematopoietic stem cell transplant.
Children weighing 30 kg and above Usual dose 480 mg once a day
- 480 mg once daily: one 480 mg tablet or two 240 mg tablets
- Or four 120 mg packets of oral pellets
Children 15 kg to less than 30 kg Usual dose 240 mg once a day
- 240 mg once daily: one 240 mg tablet or two 120 mg packets of oral pellets
Children 7.5 kg to less than 15 kg Usual dose 120 mg once a day
- 120 mg once daily: one 120 mg packet of oral pellets (tablets not recommended)
Children 6 kg to less than 7.5 kg Usual dose 80 mg once a day
- 80 mg once daily: four 20 mg packets of oral pellets (tablets not recommended)
Children 30 kg and above also taking cyclosporine Usual dose 240 mg once a day
- 240 mg once daily: one 240 mg tablet or two 120 mg packets of oral pellets
Good to know
Co-administered with cyclosporine
Children 15 kg to less than 30 kg also taking cyclosporine Usual dose 120 mg once a day
- 120 mg once daily: one 120 mg packet of oral pellets (tablets not recommended)
Good to know
Co-administered with cyclosporine
Children 7.5 kg to less than 15 kg also taking cyclosporine Usual dose 60 mg once a day
- 60 mg once daily: three 20 mg packets of oral pellets (tablets not recommended)
Good to know
Co-administered with cyclosporine
Children 6 kg to less than 7.5 kg also taking cyclosporine Usual dose 40 mg once a day
- 40 mg once daily: two 20 mg packets of oral pellets (tablets not recommended)
Good to know
Co-administered with cyclosporine
Preventing CMV disease after a kidney transplant
For adults and children 12 years and older weighing at least 40 kg
Usual dose 480 mg once a day
- 480 mg once daily orally (one 480 mg tablet or two 240 mg tablets
- Four 120 mg packets of oral pellets for patients who cannot swallow tablets) through 200 days post-transplant
Good to know
Initiate between Day 0 and Day 7 post-transplant
Adults and pediatric patients 12 years and older (HSCT at least 30 kg or kidney transplant at least 40 kg) taking cyclosporine
For adults and children 12 years and older also taking cyclosporine
Usual dose 240 mg once a day
Good to know
If cyclosporine is started later, next dose is 240 mg once daily; if stopped, next dose is 480 mg once daily
HSCT stands for hematopoietic stem cell transplant.
Letermovir Injection
Preventing CMV infection after a stem cell transplant
Adults and children 12 years and older weighing at least 30 kg Usual dose 480 mg once a day
- 480 mg once daily as an IV infusion over 1 hour through 100 days post-HSCT
Good to know
May be continued through Day 200 post-HSCT in patients at risk for late CMV infection
HSCT stands for hematopoietic stem cell transplant.
IV means given into a vein (intravenous).
Children 30 kg and above Usual dose 480 mg once a day
- 480 mg once daily IV
IV means given into a vein (intravenous).
Children 15 kg to less than 30 kg Usual dose 120 mg once a day
- 120 mg once daily IV
IV means given into a vein (intravenous).
Children 7.5 kg to less than 15 kg Usual dose 60 mg once a day
- 60 mg once daily IV
IV means given into a vein (intravenous).
Children 6 kg to less than 7.5 kg Usual dose 40 mg once a day
- 40 mg once daily IV
IV means given into a vein (intravenous).
Preventing CMV disease after a kidney transplant
For adults and children 12 years and older weighing at least 40 kg
Usual dose 480 mg once a day
- 480 mg once daily as an IV infusion over 1 hour through 200 days post-transplant
IV means given into a vein (intravenous).
Injection with cyclosporine
For adults and children 12 years and older also taking cyclosporine
Usual dose 240 mg once a day
Good to know
Co-administered with cyclosporine
Side Effects
The most commonly reported side effects during clinical trials include:
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Swelling in the legs or feet (peripheral edema)
- Cough
- Headache
- Fatigue
- Abdominal pain
When to get medical help
- Call your doctor if you notice signs of a serious drug interaction — such as unusual muscle pain or weakness, which could signal a rare but dangerous condition called rhabdomyolysis (muscle breakdown)
- Tell your doctor right away if you experience an allergic reaction, such as difficulty breathing, rash, or swelling
- If you receive the IV form and have kidney problems, report any decrease in urine output or signs of worsening kidney function to your care team
- Tell your doctor about any new or worsening heart symptoms, such as rapid or irregular heartbeat
- Contact your care team if you experience any hearing changes, especially if receiving the IV form
A higher rate of cardiac events such as rapid heartbeat (tachycardia) and atrial fibrillation was seen in Prevymis-treated stem cell transplant patients compared to placebo — though most were mild to moderate. Let your care team know right away if you experience a fast or irregular heartbeat, difficulty breathing, severe allergic reaction, or unusual muscle pain or weakness.
Warnings and Precautions
- Drug interactions are the biggest concern. Prevymis affects and is affected by many medications commonly used in transplant care. Some combinations are prohibited entirely (pimozide, ergot alkaloids, and certain statins with cyclosporine). Others require close monitoring or dose changes. Your full medication list must be reviewed before and throughout treatment.
- IV form contains hydroxypropyl betadex. This inactive ingredient can accumulate in patients with reduced kidney function. Animal studies have shown it may affect hearing. The IV form should only be used when oral treatment is not possible, and for no longer than 4 weeks if avoidable. Kidney function should be monitored closely in patients with significant renal impairment using the IV form.
- Severe liver disease: Prevymis is not recommended for patients with severe hepatic (liver) impairment.
Interactions
Prevymis has a wide range of significant drug interactions — always share your full medication list with your prescriber and pharmacist before starting.
- Pimozide: Contraindicated — Prevymis raises pimozide levels, risking dangerous heart rhythm problems (QT prolongation, torsades de pointes).
- Ergot alkaloids (ergotamine, dihydroergotamine): Contraindicated — Prevymis raises their levels, risking ergotism (severe, dangerous blood vessel spasm).
- Pitavastatin and simvastatin + cyclosporine: Contraindicated — the combination dramatically raises statin levels, risking serious muscle damage (myopathy or rhabdomyolysis).
- Cyclosporine: Raises letermovir levels significantly; a lower Prevymis dose is required when these are taken together.
- Other statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin): Prevymis increases their levels; dose limits or reductions apply; monitor for muscle pain.
- Tacrolimus and sirolimus (transplant immunosuppressants): Prevymis raises blood levels; frequent monitoring and dose adjustment of these drugs are needed.
- Warfarin: Prevymis lowers warfarin levels; monitor INR closely to maintain anticoagulation.
- Carbamazepine, phenobarbital, phenytoin, rifampin, rifabutin, nafcillin, St. John's Wort, efavirenz, etravirine, nevirapine, bosentan, modafinil, thioridazine: These can reduce Prevymis levels, potentially making it less effective; co-use is generally not recommended.
- Antidiabetic agents (glyburide, repaglinide, rosiglitazone): Prevymis may raise their levels; monitor blood glucose closely.
- Proton pump inhibitors (omeprazole, pantoprazole): Prevymis may lower their levels; clinical monitoring may be needed.
Interactions Listed in the FDA-Approved Label
From the Letermovir prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
What happensIncreases cyclosporine and letermovir concentrations.What to doDecrease PREVYMIS to 240 mg once daily in patients 12 years and older; frequently monitor cyclosporine whole blood concentrations.
-
What happensIncreases pimozide; risk of QT prolongation and torsades de pointes.What to doCo-administration is contraindicated.
-
Ergotamine, dihydroergotamineWhat happensIncreases ergot alkaloid concentrations; risk of ergotism.What to doCo-administration is contraindicated.
-
Pitavastatin, simvastatinWhat happensIncreases HMG-CoA reductase inhibitor concentrations.What to doNot recommended; contraindicated with cyclosporine.
-
What happensIncreases atorvastatin concentrations.What to doDo not exceed atorvastatin 20 mg daily; monitor for myopathy and rhabdomyolysis; not recommended with cyclosporine.
-
Rifampin, rifabutinWhat happensDecreases letermovir concentrations.What to doCo-administration is not recommended due to potential loss of efficacy.
-
Carbamazepine, phenobarbital, phenytoinWhat happensDecreases letermovir concentrations.What to doCo-administration is not recommended due to potential loss of efficacy.
-
St. John's wortWhat happensDecreases letermovir concentrations.What to doCo-administration is not recommended due to potential loss of efficacy.
-
What happensDecreases warfarin concentrations.What to doFrequently monitor INR.
-
Tacrolimus, sirolimusWhat happensIncreases tacrolimus or sirolimus concentrations.What to doFrequently monitor whole blood concentrations during and after PREVYMIS and adjust the dose.
Read the label’s full interactions text
7 DRUG INTERACTIONS Dosage Adjustment: If PREVYMIS is co-administered with cyclosporine, the dosage of PREVYMIS should be decreased to 240 mg once daily in adult and pediatric patients 12 years of age and older. If PREVYMIS is co-administered with cyclosporine in pediatric patients less than 12 years of age, dose adjustment may be required. Co-administration of PREVYMIS may alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of PREVYMIS. Consult the full prescribing information prior to and during treatment for potential drug interactions. 7.1 Potential for Other Drugs to Affect PREVYMIS Letermovir is a substrate of organic anion-transporting polypeptide 1B1/3 (OATP1B1/3) and P-glycoprotein (P-gp) transporters and UDP-glucuronosyltransferase 1A1/3 (UGT1A1/3) enzymes. Co-administration of PREVYMIS with drugs that are inhibitors of OATP1B1/3 transporters may result in increases in letermovir plasma concentrations (Table 11). Co-administration of PREVYMIS with inducers of transporters (e.g., P-gp) and/or enzymes (e.g., UGTs) is not recommended due to the potential for a decrease in letermovir plasma concentrations (see Table 11 ). 7.2 Potential for PREVYMIS to Affect Other Drugs Co-administration of PREVYMIS with midazolam results in increased midazolam plasma concentrations, indicating that letermovir is a moderate inhibitor of CYP3A. Co-administration of PREVYMIS with drugs that are CYP3A substrates may result in clinically relevant increases in the plasma concentrations of co-administered CYP3A substrates (Table 11). Letermovir is an inhibitor of OATP1B1/3 transporters.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Current medications: Tell your prescriber about every drug, supplement, and herbal product you take — the interaction list for Prevymis is long and includes common transplant medications.
- Kidney problems: If you have reduced kidney function and will use the IV form, your care team must monitor your kidney function closely due to buildup of the IV vehicle (hydroxypropyl betadex).
- Liver problems: Prevymis is not recommended for patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment is needed for mild or moderate liver disease.
- Pregnancy: Animal studies showed potential harm to fetuses; the risk to human pregnancies is not fully known. Discuss with your doctor if you are pregnant or planning to become pregnant.
- Breastfeeding: It is not known if letermovir passes into human breast milk. Weigh the benefits of breastfeeding against potential risks with your doctor.
- Children: Prevymis is approved for stem cell transplant recipients as young as 6 months (weighing at least 6 kg), but is not established for kidney transplant patients under 12 years old or under 40 kg.
- Older adults: No dose adjustment is needed based on age alone; safety and efficacy were similar across age groups in clinical trials.
Overdose
There is no specific antidote for a Prevymis overdose. If too much is taken, medical staff will monitor for side effects and provide supportive treatment as needed. It is not known whether dialysis can meaningfully remove letermovir from the body.
Half-Life and How Your Body Processes It
After an oral dose, letermovir is absorbed relatively quickly, with peak blood levels reached within about 1.5 to 3 hours. Food does not meaningfully change the total amount absorbed (though it can modestly increase the peak level), so tablets can be taken with or without a meal. Letermovir is very heavily bound to proteins in the blood (about 99%) and is eliminated primarily through the liver; about 93% of a dose leaves the body through the feces. The drug has a half-life of roughly 12 hours, and steady blood levels are reached after about 9 to 10 days. Oral bioavailability (how much of the drug reaches the bloodstream) varies by patient population and whether cyclosporine is used at the same time — cyclosporine significantly increases letermovir exposure, which is why a dose adjustment is required.
Storage
Store PREVYMIS tablets in the original package until use to protect from moisture. Store PREVYMIS tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Letermovir: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Letermovir — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Prevymis being used for in my situation?
Can I take my tablet with food, or does it need to be on an empty stomach?
What side effects should I expect, and when should I call my doctor?
I'm on several other medications for my transplant. Is that a problem with Prevymis?
I'm getting the IV form in the hospital. Is that the same as the pill?
Is Prevymis safe during pregnancy?
Is letermovir available over the counter?
When was letermovir first available?
What is the brand name of letermovir?
What is the generic name of Prevymis?
What drug class is letermovir?
What strengths does letermovir come in?
How much does letermovir cost?
Is there a letermovir shortage?
Where can I read the letermovir prescribing information (package insert)?
Can you crush letermovir?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Letermovir
Skip the scrolling. Ask in your own words and get an answer from Letermovir’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Letermovir’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Letermovir on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Letermovir Forms and Strengths (How It Comes)
Letermovir comes in 3 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Letermovir inactive ingredients by manufacturer.
Injection
How this form is used
- Prevymis injection is used to help prevent cytomegalovirus (CMV) infection and disease in certain stem cell transplant recipients and high-risk kidney transplant recipients.
- Prevymis injection is meant only for people who cannot take oral therapy.
- Prevymis injection must be diluted before it is given, and it is given through a sterile in-line filter.
- Prevymis injection is given as an infusion into a vein at a constant rate over 1 hour, once daily. It is not given as a quick bolus injection.
- Prevymis injection users are switched to oral Prevymis as soon as they can take medicine by mouth. If possible, intravenous use should not go beyond 4 weeks.
- Prevymis injection should not be used with IV bags or infusion sets that contain the plasticizer DEHP.
Oral pellets
How this form is used
- Prevymis oral pellets are used to help prevent CMV infection and disease in certain stem cell transplant recipients and high-risk kidney transplant recipients.
- Prevymis oral pellets can be used for people who cannot swallow tablets, and are an option for some young children based on their weight.
- Prevymis oral pellets are given by mouth mixed with soft food, or through a nasogastric or gastric feeding tube.
- Prevymis oral pellets should not be crushed or chewed.
- Prevymis oral pellets are taken once daily, using one or more packets as directed by the prescriber. Follow the Instructions for Use for preparing them.
Tablet
How this form is used
- Prevymis tablets are used to help prevent CMV infection and disease in certain stem cell transplant recipients and high-risk kidney transplant recipients.
- Prevymis tablets are taken by mouth once daily, with or without food.
- Prevymis tablets should be swallowed whole.
- Prevymis tablets are not recommended for some smaller children based on their weight; the prescriber chooses the right form.
Letermovir on the U.S. Market: Products, Makers and Brands
How Letermovir appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 6 Letermovir product records with the FDA, mostly as injection, oral pellets, tablet; the earliest marketing or approval year on record is 2017. The one brand name in the directory today is Prevymis; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (3) · Unfinished tablet, film coated (2) · Unfinished injection, powder, for solution (1) · Unfinished injection, solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Letermovir Is Used (Medicaid Data)
How many Letermovir prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Letermovir prescribed? Of the 1,682 medications we measure, Letermovir ranks #1,095 by Medicaid prescriptions — more than 35% of them.
Utilization by Letermovir product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
letermovir 480 MG Oral Tablet Most dispensed
2 of 5 listed NDCs had Medicaid claims. RxNorm 1988673
letermovir 240 MG Oral Tablet
2 of 5 listed NDCs had Medicaid claims. RxNorm 1988666
letermovir 120 MG Oral Pellet
1 of 2 listed NDCs had Medicaid claims. RxNorm 2693191
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 5 of the 12 listed Letermovir NDCs had Medicaid claims.
Compare Letermovir Products
A representative set of FDA-listed product records for Letermovir — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 20 mg/mL | Intravenous | Merck Sharp & Dohme LLC × 2 listings | NDA | View NDC → |
| 💊Oral pellets | ||||
| 20 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 120 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 💊Tablet | ||||
| 240 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 480 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
Showing 6 of 6 products — FDA National Drug Code Directory. See every product, package size and price: browse all 6 Letermovir NDCs →
Letermovir Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Letermovir — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Letermovir in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Letermovir FDA Approval History
How Letermovir went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Letermovir Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Letermovir recalls since July 2021.
✅No Letermovir recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Letermovir in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 3
- Strengths
- 6
- Forms in current FDA listings
- 3 of 3
RxCUI 1988648 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1988651Its 2 strengths (SCD)-
12 mL letermovir 20 mg/mL
RxCUI 1988652 -
24 mL letermovir 20 mg/mL
RxCUI 1988660
-
12 mL letermovir 20 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Letermovir Supply and Shortage Status
Whether Letermovir is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Medicaid Pays for Letermovir
CMS’s weekly pharmacy survey (NADAC) has no price for Letermovir, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.
No price was found for Letermovir injections or oral pellets, so the prices below are for the tablets only.
| Form | Strength | Version | What Medicaid paid | |
|---|---|---|---|---|
| Tablet · Oral | 240 mg | Prevymis (brand) | $270.21 per tablet | NDC details & Medicaid use |
| Tablet · Oral | 480 mg | Prevymis (brand) | $270.60 per tablet | NDC details & Medicaid use |
Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.
Letermovir Brand Names
Letermovir has one brand name on record: Prevymis. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Letermovir: Manufacturers and Labelers
One company lists Letermovir products with the FDA. By number of product records, the largest are Merck Sharp & Dohme LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Letermovir Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Merck Sharp & Dohme LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →